Main Menu

Aratana Therapeutics, Inc.

(NASDAQ GM: PETX)

Summary

Attention investors who purchased shares of Aratana Therapeutics, Inc. before April 26, 2019:

Rigrodsky & Long is investigating potential claims against the board of directors of Aratana Therepeutics, Inc. concerning possible breaches of fiduciary duty and other violations of law related to the Company’s agreement to be acquired by Elanco Animal Health Incorporated. 

Press Release

Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Aratana Therapeutics, Inc. (“Aratana” or the “Company”) (NASDAQ GM: PETX) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to be acquired by Elanco Animal Health Incorporated (“Elanco”) (NYSE: ELAN). Under the terms of the agreement, shareholders of Aratana will receive 0.1481 shares of Elanco common stock and one contingent value right for each share of Aratana common stock.

If you own common stock of Aratana and purchased any shares before April 26, 2019, if you would like to learn more about this investigation, or if you have any questions concerning this announcement or your rights or interests, please contact Seth D. Rigrodsky or Gina M. Serra toll-free at (888) 969-4242 or by e-mail at info@rl-legal.com.  

Rigrodsky & Long, P.A., with offices in Delaware, New York, and California, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in numerous cases nationwide, including federal securities fraud actions, shareholder class actions, and shareholder derivative actions.

Attorney advertising.  Prior results do not guarantee a similar outcome.

Back to Page